Can fibroblast growth factor 23 fine-tune therapies for diseases of abnormal mineral ion metabolism?
- 9 October 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Clinical Practice Endocrinology & Metabolism
- Vol. 3 (12), 788-789
- https://doi.org/10.1038/ncpendmet0667
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- How Fibroblast Growth Factor 23 WorksJournal of the American Society of Nephrology, 2007
- Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily MembersMolecular and Cellular Biology, 2007
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006
- Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolismCurrent Opinion in Nephrology and Hypertension, 2006
- The Roles of Specific Genes Implicated as Circulating Factors Involved in Normal and Disordered Phosphate Homeostasis: Frizzled Related Protein-4, Matrix Extracellular Phosphoglycoprotein, and Fibroblast Growth Factor 23Endocrine Reviews, 2006
- Premature aging‐like phenotype in fibroblast growth factor 23 null mice is a vitamin D‐mediated processThe FASEB Journal, 2006
- Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patientsKidney International, 2005
- Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patientsKidney International, 2005
- FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate HomeostasisJournal of Bone and Mineral Research, 2004
- Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteersKidney International, 2003